Wellfully Limited

WFL

AU0000105033

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 06:02:13 21/07/2023 BST			5-day change	1st Jan Change
0.003 ^AUD	-.--%		-.--%	-.--%

04-08	Wellfully Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI
02-29	Wellfully Limited Reports Earnings Results for the Full Year Ended June 30, 2023	CI

Wellfully Limited announced that it expects to receive AUD 0.26 million in funding from Celtic Capital Pty. Ltd.

January 22, 2023

Wellfully Limited announced that it has enter has entered into a secured convertible loan facility agreement with Celtic Capital Pty Ltd for a private placement of AUD 260,000 on January 23, 2023.

Latest news about Wellfully Limited

Wellfully Limited Reports Earnings Results for the Half Year Ended December 31, 2023	04-08	CI
Wellfully Limited Reports Earnings Results for the Full Year Ended June 30, 2023	02-29	CI
Wellfully Limited Announces Bill Pavlovski Steps Down from His Role as Non-Executive Director	20/06/23	CI
Wellfully Limited Announces Board Changes	09/06/23	CI
Wellfully Limited Appoints John Forrester as Director	18/05/23	CI
Wellfully Limited Announces Address Changes	10/05/23	CI
Wellfully Receives R&D Tax Refund	27/04/23	MT
Wellfully Completes AU$1.5 Million Placement	06/04/23	MT
Wellfully Limited Reports Earnings Results for the Half Year Ended December 31, 2022	06/04/23	CI
Wellfully Limited Announces Executive Changes	22/03/23	CI
Wellfully Limited Advises Delayed in Reporting its Financial Results for the Six Month Period Ended 31 December 2022	27/02/23	CI
Wellfully Limited announced that it expects to receive AUD 0.26 million in funding from Celtic Capital Pty. Ltd.	22/01/23	CI
Wellfully Limited Appoints David Wheeler as Non-Executive Director, Effective from 1 February 2023	09/01/23	CI
Wellfully Secures Convertible Loan	30/12/22	MT
Wellfully Taps Consulting Firm to Assist in Frankfurt Dual Listing	30/12/22	MT
Wellfully Limited Announces Step Down of Steven Schapera as Non-Executive Director, Effective 31 December 2022	29/12/22	CI
Wellfully Signs Pact to Merge Wellness Marketing Company with Self	06/12/22	MT
Wellfully Limited entered into a non-binding memorandum of understanding to acquire The Brandbase from Capital D Management LLP for AUD 2.8 million.	05/12/22	CI
Wellfully Limited Appoints Andy Wortlock as Non-Executive Director	18/11/22	CI
Wellfully Seeks Extension of Voluntary Suspension	17/11/22	MT
Wellfully Temporarily Halts Trading	15/11/22	MT
Wellfully Issues More Than 21 Million Ordinary Shares	04/11/22	MT
Wellfully's Lugano-based Facility Receives GMP Certification	03/10/22	MT
Wellfully Limited's Swiss Facility Receives GMP Certification	02/10/22	CI
Wellfully Limited Auditor Raises 'Going Concern' Doubt	01/10/22	CI

Wellfully Limited is an Australia-based fully integrated, science-based wellness company. The Company has developed physical enhancement technologies based on the interactions between ingredient molecules and weak atomic forces. Its brands include REDUIT and SWISSWELL. Its REDUIT brand designs technology-enhanced skincare and haircare treatments, and its technologies include ultrasonic diffusion and magnetic misting. SWISSWELL is a biotechnology brand that offers a technology-enhanced joint management system, the Swisswell Knee Patch. Swisswell is an adhesive knee patch worn on the knee to lubricate the joint before, during and after physical activity. It also offers a portfolio of technologies and support partners by providing Internet Protocol (IP) and has capabilities in magnetic array design, and claims testing, engineering and production. It is focused on both large and small companies across a range of market sectors, including cosmetics and skincare, and consumer healthcare.

Sector

Biotechnology & Medical Research

Calendar

25/02/2025 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
WELLFULLY LIMITED	-.--%	979K
MODERNA, INC.	+29.03%	49.18B
IQVIA HOLDINGS INC.	-0.10%	42.11B
LONZA GROUP AG	+43.45%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+11.48%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.71B
BIO-TECHNE CORPORATION	+9.06%	13.26B
MEDPACE HOLDINGS, INC.	+30.01%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.99B